TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23321318
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with PegIFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 48 weeks
Study: 17629162
Drug: Daflon (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon (500 mg twice/daily for six months)
Study: 17629162
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin pill)
Study: 362213
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glucose
Study: 23454402
Drug: Desmopressin 50
Normalized name: desmopressin acetate 55.3 MCG (desmopressin 50 MCG) Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 50 μg
Study: 23454402
Drug: Desmopressin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 75 μg
Study: 22142351
Drug: Carvedilol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (80 mg, once daily for 4 weeks)
Study: 22142351
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg, once daily for 4 weeks)
Study: 18647845
Drug: Acetaminophen, ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, ibuprofen, and/or 4% lidocaine gel
Study: 12874748
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 220 mg per day for 6 weeks
Study: 12874748
Drug: Placebo (dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dummy pill)
Study: 9128016
Drug: Low-dose prostaglandin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prostaglandin E1 (PGE1) at a rate of 0.2 microgram.kg‐1.min‐1 throughout surgery
Study: 3555016
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (slow‐release aspirin and dipyridamole)
Study: 22924259
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to guidelines (British National Formulary - BNF, and Senford Guide)
Study: 11790467
Drug: Ordinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary treatment
Study: 17032157
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy in addition to treatment as usual
Study: 10669153
Drug: Fluvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin therapy for 4 weeks
Study: 9322469
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) guidance with 20 mL bupivacaine 0.5%
Study: 9322469
Drug: Nerve stimulator
Normalized name: nerve stimulator device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulator (NS) with 20 mL bupivacaine 0.5%
Study: 30612134
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac Sodium (75 mg)
Study: 28580504
Drug: Emotion-Focused Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotion-Focused Cognitive-Behavioral Therapy (ECBT)
Study: 28580504
Drug: Traditional Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Cognitive-Behavioral Therapy (CBT)
Study: 26322555
Drug: Caffeine (∼
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (∼ 5 mg · kg(‐1) body weight)
Study: 22913676
Drug: LCAF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCAF with concurrent chemotherapy (LCAF + CT)
Study: 19969511
Drug: Preoperative radio-chemotherapy
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative radio-chemotherapy (RCT)
Study: 17391930
Drug: donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil 5 mg for 6 weeks then donepezil 10 mg for six weeks
Study: 15359055
Drug: Advanced practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced practice nursing support (telephone calls from an APN twice in the first week and weekly for 4 weeks)
Study: 11260420
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VP and Qa monitoring
Study: 8004731
Drug: Intubation following
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intubation following induction of anaesthesia with thiopentone 5 mg.kg‐1 and succinylcholine 2 mg.kg‐1
Study: 2537830
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine (C) against yellow fever and measles
Study: 2537830
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine only (A)
Study: 2537830
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine only (B)
Study: 15231512
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy (D2E7, adalimumab, Humira)
Study: 30828762
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with diuretics and vasodilators
Study: 30828762
Drug: Novel treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel treatments under development
Study: 23751132
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) for 12 weeks
Study: 19881973
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin 200 U/day + physical therapy (n = 23)
Study: 19881973
Drug: Paracetamol 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1,500 mg/day + physical therapy (n = 22)
Study: 16891222
Drug: Standard nicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nicotinamide (1.2 g/m2)
Study: 11275164
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg extended-release oxybutynin
Study: 11275164
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tolterodine (2 mg twice a day)
Study: 9223394
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg bezafibrate
Study: 8477565
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg perindopril once daily
Study: 8477565
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg perindopril twice daily
Study: 28430684
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil (1.5 mg/kg)
Study: 23905378
Drug: Bushen quhan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen quhan zhiwang decoction (BQZD) combined with methotrexate (MTX) 10 mg/week
Study: 23905378
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 10 mg/week alone
Study: 10855632
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (once-daily, subcutaneous)
Study: 10855632
Drug: Standard, continuous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard, continuous, adjusted-dose intravenous heparin
Study: 9115057
Drug: Intravenous fenoldopam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fenoldopam (titrated up to 0.5 microgram/kg/min)
Study: 9115057
Drug: Intravenous fenoldopam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fenoldopam
Study: 8327167
Drug: Forane (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forane (inhalation anesthetic)
Study: 8327167
Drug: Forane (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forane (inhalation anesthetic) at higher concentration
Study: 8327167
Drug: Intravenous anesthetic
Normalized name: Intravenous anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthetic
Study: 3302005
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg twice daily
Study: 27488081
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg twice per day
Study: 24237751
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 10% solution once daily for 2 months
Study: 24237751
Drug: Hydroquinone 4%
Normalized name: HYDROQUINONE 4% CREAM
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroquinone 4% solution once daily for 2 months
Study: 20083352
Drug: Topical clonazepam
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical clonazepam
Study: 18597830
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg once daily titrated to 100 mg once daily)
Study: 11929471
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy and combined treatments
Study: 9673439
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral D‐fenfluramine
Study: 2500718
Drug: Oral enoxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enoxacin 400 mg
Study: 2500718
Drug: Intramuscular ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceftriaxone 250 mg
Study: 31373430
Drug: Lateral approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral approach injection of 40 mg/ml triamcinolone acetonide (Kenalog) and 4 ml 1% lignocaine
Study: 31373430
Drug: Posterior approach
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior approach injection of 40 mg/ml triamcinolone acetonide (Kenalog) and 4 ml 1% lignocaine
Study: 28701593
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 2 μg/kg/min following anesthesia induction till the end of the surgery
Study: 22974973
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) 1200 mg catechins, 240 mg caffeine/day for 7 days
Study: 21375794
Drug: Hydrocortisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (30 mg)
Study: 21375794
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg) + Hydrocortisone (30 mg)
Study: 26669965
Drug: Dianatal obstetric
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dianatal obstetric gel
Study: 26669965
Drug: Control (labor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (labor management without obstetric gel)
Study: 17932127
Drug: Azithromycin 1
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1 g stat.
Study: 17932127
Drug: Extended azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extended azithromycin (500 mg on day 1 followed by 250 mg daily for 4 days)
Study: 17932127
Drug: Extended doxycycline
Normalized name: doxycycline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended doxycycline treatment
Study: 7741777
Drug: Slow-release propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release propafenone 2 x 225 mg
Study: 7741777
Drug: Slow-release propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release propafenone 2 x 325 mg
Study: 7741777
Drug: Slow-release propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release propafenone 2 x 425 mg
Study: 7741777
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of slow-release propafenone
Study: 1784666
Drug: Humorous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humorous treatment (humor condition)
Study: 29846832
Drug: Helium-neon laser
Normalized name: neon
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helium-neon laser therapy (HNLT) and conventional therapy
Study: 29846832
Drug: Infrared laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared laser therapy (ILT) and conventional therapy
Study: 26824517
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance exercise (PRE) with 0.5 kg dumbbell, performed twice a day for 8 weeks after complex decongestive physiotherapy
Study: 24916467
Drug: EVLTAP (endovenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVLTAP (endovenous laser therapy with ambulatory phlebectomy)
Study: 24916467
Drug: EVLA alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVLA alone with sequential phlebectomy
Study: 7986236
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba special extract LI 1370 (Kaveri forte) 150 mg daily
Study: 2919733
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg every 6 hours for 72 hours)
Study: 31243685
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg chromium
Study: 25789270
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 2% (10 ml every 3 hours, six times a day for 6 days)
Study: 25789270
Drug: Magic mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magic mouthwash (10 ml every 3 hours, six times a day for 6 days)
Study: 24165976
Drug: Fedratinib (10-680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fedratinib (10-680 mg)
Study: 22023525
Drug: ATG 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG 7.5 mg/kg
Study: 7721404
Drug: Irbesartan 50
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan 50 mg
Study: 9607385
Drug: Irbesartan 200
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan 200 mg
Study: 9607385
Drug: Irbesartan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (all doses > or = 50 mg)
Study: 9607385
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg added to irbesartan
Study: 352788
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg per day)
Study: 30993836
Drug: BAY 81-8973
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 81-8973 low-dose prophylaxis (20-30 IU/kg twice-weekly)
Study: 30993836
Drug: BAY 81-8973
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 81-8973 high-dose prophylaxis (30-40 IU/kg 3 times weekly)
Study: 28255768
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 mcg)
Study: 10420862
Drug: Physicians' ratings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physicians' ratings of depression severity before treatment and at 6 months
Study: 2317420
Drug: 0.5% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% plain bupivacaine 4 ml at the L2‐3 spinal interspace (n = 20)
Study: 2317420
Drug: 0.5% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% plain bupivacaine 4 ml at the L4‐5 spinal interspace (n = 20)
Study: 24286968
Drug: Codeine-containing cough
Normalized name: chlorpheniramine / codeine / phenylephrine Oral Solution [Endal Cough]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine-containing cough syrups (CCS) users
Study: 20686477
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg twice-daily (b.i.d.)
Study: 17868430
Drug: Enoxaparin 30
Normalized name: ENOXAPARIN 30MG/0.3ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 30 mg b.i.d.
Study: 20686477
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in daily steady-state AUC(ss) of 1 microg x h/ml
Study: 10449212
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate aerosol (ISA) 2.5 mg
Study: 2169714
Drug: nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nedocromil sodium 1% nasal solution (Tilarin, QID, Fisons plc)
Study: 7449793
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium carbonate
Study: 23872464
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg APD421
Study: 23872464
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg APD421
Study: 23872464
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg APD421
Study: 21734596
Drug: 3,4-diaminopyridine (3,4-DAP)
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3,4-diaminopyridine (3,4-DAP) 10 mg
Study: 21734596
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) 10 mg
Study: 16169160
Drug: Gabapentin 3200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 3200 mg (1600 mg bid)
Study: 1800180
Drug: Topical cysteamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cysteamine 0.2% six times a day
Study: 31415608
Drug: On-demand medication
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand medication
Study: 3170992
Drug: Allergoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergoid treatment
Study: 22340224
Drug: Sufentanil 0.2
Normalized name: ropivacaine-sufentanil 0.2%-1 mcg/mL-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.2 µg/kg
Study: 22340224
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 µg/kg
Study: 19057893
Drug: Thiamine therapy
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine therapy (3 x 100 mg capsules per day for 3 months)
Study: 19057893
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 capsules per day for 3 months)
Study: 19057893
Drug: Thiamine therapy
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine therapy
Study: 19057893
Drug: Thiamine therapy
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine therapy and Placebo
Study: 17464511
Drug: Once-daily loratadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily loratadine 10 mg-pseudoephedrine 240 mg sustained release tablets
Study: 17464511
Drug: Twice-daily loratadine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily loratadine 5 mg-pseudoephedrine 120 mg combination tablets
Study: 9924909
Drug: Self-administration (S)
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administration (S)
Study: 7774736
Drug: Low amniotomy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low amniotomy and oxytocin titration (Group B)
Study: 7774736
Drug: Intra-cervical Foley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-cervical Foley balloon overnight followed by low amniotomy and oxytocin titration (Group C)
Study: 2183884
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg twice daily for 1 week)
Study: 2183884
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg twice daily for 2 weeks)
Study: 452602
Drug: L-dopa plus
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa plus decarboxylase inhibitors (carbidopa, benserazide)
Study: 452602
Drug: L-dopa (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (plasma levels)
Study: 21441783
Drug: RV5 between
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV5 between doses 1 and 2
Study: 21441783
Drug: RV5 between
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV5 between doses 2 and 3
Study: 19743457
Drug: CoQ10 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 at 2,700 mg/day for 9 months
Study: 15117088
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg and 20 mg
Study: 11692016
Drug: Aspirin (n=49)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (n=49)
Study: 11692016
Drug: Low-dose low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose low-molecular-weight heparin (LMWH) (n=86)
Study: 11692016
Drug: Both Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both Aspirin and LMWH
Study: 9515282
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 mg bid)
Study: 9515282
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg tid)
Study: 8410124
Drug: Chemotherapy (96
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (96 patients)
Study: 22105591
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg/d
Study: 28419992
Drug: Extended slow-dose
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended slow-dose transfusion (ESDT), half an SDP unit administered over 4 hours
Study: 19184428
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide (group A)